About: Multiple sclerosis management during the COVID-19 pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Multiple sclerosis management during the COVID-19 pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Multiple sclerosis management during the COVID-19 pandemic
Creator	Cohen, Jeffrey Montalban, Xavier Aravidis, Berna Arrambide, Georgina Bermel, Robert Carbonell-Mirabent, Pere Cárdenas-Robledo, Simón Douglas, Morgan Fitzgerald, Kathryn Hellisz, Kelsey Hua, Le Hudec, Timothy Husak, Scott Mahajan, Kedar Moss, Brandon Mowry, Ellen Ogbuokiri, Esther Ontaneda, Daniel Rodríguez-Barranco, Marta Sastre-Garriga, Jaume Tagliani, Paula Tintore, Mar Wang, Zhini Weber, Malory Zabalza, Ana Mcginley, Marisa
Source	Medline; PMC
abstract	BACKGROUND: People with multiple sclerosis (MS) may be at higher risk for complications from the 2019 coronavirus (COVID-19) pandemic due to use of immunomodulatory disease modifying therapies (DMTs) and greater need for medical services. OBJECTIVES: To evaluate risk factors for COVID-19 susceptibility and describe the pandemic’s impact on healthcare delivery. METHODS: Surveys sent to MS patients at Cleveland Clinic, Johns Hopkins, and Vall d’Hebron-Centre d’Esclerosi Múltiple de Catalunya in April and May 2020 collected information about comorbidities, DMTs, exposures, COVID-19 testing/outcomes, health behaviors, and disruptions to MS care. RESULTS: There were 3028/10,816 responders. Suspected or confirmed COVID-19 cases were more likely to have a known COVID-19 contact (odds ratio (OR): 4.38; 95% confidence interval (CI): 1.04, 18.54). In multivariable-adjusted models, people who were younger, had to work on site, had a lower education level, and resided in socioeconomically disadvantaged areas were less likely to follow social distancing guidelines. 4.4% reported changes to therapy plans, primarily delays in infusions, and 15.5% a disruption to rehabilitative services. CONCLUSION: Younger people with lower socioeconomic status required to work on site may be at higher exposure risk and are potential targets for educational intervention and work restrictions to limit exposure. Providers should be mindful of potential infusion delays and MS care disruption.
has issue date	2020-08-10(xsd:dateTime)
bibo:doi	10.1177/1352458520948231
bibo:pmid	32772807
has license	cc-by
sha1sum (hex)	34399d229de5689a18a9bbed9eeb2ee1c8bcfcc5
schema:url	https://doi.org/10.1177/1352458520948231
resource representing a document's title	Multiple sclerosis management during the COVID-19 pandemic
has PubMed Central identifier	PMC7424611
has PubMed identifier	32772807
schema:publication	Mult Scler
resource representing a document's body	covid:34399d229de5689a18a9bbed9eeb2ee1c8bcfcc5#body_text
is schema:about of	named entity 'services' named entity 'contact' named entity 'management' named entity 'COVID-19' named entity 'EVALUATE' named entity 'INFORMATION' named entity 'HEALTHCARE DELIVERY' named entity 'MULTIPLE SCLEROSIS' named entity 'Results' named entity 'collected' named entity 'susceptibility' named entity 'immunomodulatory' named entity 'pandemic' named entity 'immunomodulatory' named entity 'medical services' named entity 'comorbidities' named entity 'MULTIPLE SCLEROSIS' named entity 'COVID-19 pandemic' named entity 'confidence interval' named entity 'Survey data' named entity 'patient-reported outcome' named entity 'ascertainment bias' named entity 'multiple sclerosis' named entity 'homecare' named entity 'Multiple Sclerosis' named entity 'COVID-19 pandemic' named entity 'social distancing' named entity 'COVID' named entity 'homecare' named entity 'COVID' named entity 'inflammatory' named entity 'health behaviors' named entity 'self-isolating' named entity 'occupational therapy' named entity 'COVID' named entity 'odds ratio' named entity 'Statistical methods' named entity 'asthma' named entity 'COVID' named entity 'R software' named entity 'botulinum toxin' named entity '1.04' named entity 'logistic regression' named entity 'REDCap' named entity 'immunomodulatory' named entity 'Spain' named entity 'clinical care' named entity 'odds ratio' named entity 'stroke' named entity 'observational study' named entity 'Novartis' named entity 'health services' named entity 'obesity' named entity 'non-Hispanic whites' named entity 'physical therapy' named entity 'non-adherence'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software